POSTER SESSION II: LEE B. LUSTED FINALISTS' MODERATED POSTER SESSION & CONTINENTAL BREAKFAST

Monday, October 19, 2015: 7:00 AM - 8:30 AM
Grand Ballroom EH (Hyatt Regency St. Louis at the Arch)

Each year the Lee B. Lusted Finalists Prize Student Fund recognizes students’ original research in medical decision making in order to attract the best and brightest young minds to SMDM. The 10 top-ranked student abstract submissions in each category are selected as semi-finalists for presentation during the Lee B. Lusted Finalists Moderated Poster Session. Between 7:00 AM – 8:00 AM, Lusted judges will lead moderated discussions of 5 posters in a single pod. Non-judges are welcome to process with these groups, although we request that all audience members allow judges to ask the first questions and to call on audience members with additional questions. All posters will be available for open viewing between 8:00 AM – 8:30 AM. The top two semi-finalists in each of 5 categories will receive the Lee Lusted award, announced on Wednesday, October 21 at 9:00 AM.

PS2-1

ADJUVANT HPV VACCINATION IN OLDER HIV-POSITIVE MEN WHO HAVE SEX WITH MEN FOR PREVENTION OF ANAL CANCER – LONG-TERM CLINICAL AND ECONOMIC BENEFITS
Ashish A. Deshmukh, Ph.D., M.P.H.1, Jagpreet Chhatwal, PhD1, Elizabeth Chiao, M.D., M.P.H.2, Alan Nyitray, Ph.D.3, Prajnan Das, M.D., M.S., M.P.H.1 and Scott B. Cantor, Ph.D.1, (1)The University of Texas MD Anderson Cancer Center, Houston, TX, (2)Baylor College of Medicine, Houston, TX, (3)The University of Texas School of Public Health, Houston, TX
PS2-2

A SIMPLIFIED METHOD FOR ASSESSING COST-EFFECTIVENESS OF PREDICTIVE BIOMARKERS IN ONCOLOGY
Anton Safonov1, Shi-Yi Wang, MD, PhD2, Cary P. Gross, MD1, Lajos Pusztai, MD, PhD3 and Christos Hatzis3, (1)Yale University School of Medicine, New Haven, CT, (2)Yale School of Public Health, New Haven, CT, (3)Yale Cancer Center, New Haven, CT
PS2-3

ASSESSING THE ROLE OF SEQUENCING UP TO THREE LINES OF CHEMOTHERAPY IN METASTATIC COLORECTAL CANCER TREATMENT: A COST EFFECTIVENESS ANALYSIS
Iakovos Toumazis, PhD1, Murat Kurt, PhD2, Artemis Toumazi, MS3, Loukia Karacosta, PhD1, Changhyun Kwon, PhD4 and Daniel Goldstein, MD5, (1)Stanford University, Stanford, CA, (2)Merck Research Laboratories, North Wales, PA, (3)Stem-Cell and Brain Research Institute, Lyon, France, (4)University at Buffalo, The State University of New York, Buffalo, NY, (5)Winship Cancer Institute, Emory University, Atlanta, GA
PS2-4

COST-EFFECTIVENESS OF HIV PREEXPOSURE PROPHYLAXIS FOR INJECTION DRUG USERS IN THE UNITED STATES
Cora Bernard1, Margaret L. Brandeau, PhD1, Keith Humphreys, PhD2, Eran Bendavid, MD, MS3, Mark Holodniy, MD2, Christopher Weyant, MS1, Douglas K. Owens, MD, MS2 and Jeremy D. Goldhaber-Fiebert, PhD3, (1)Department of Management Science and Engineering, Stanford University, Stanford, CA, (2)VA Palo Alto Health Care System, Palo Alto, CA, (3)Stanford Health Policy, Centers for Health Policy and Primary Care and Outcomes Research, Department of Medicine, Stanford University, Stanford, CA
PS2-5

DETERMINING THE OPTIMAL AGE TO VACCINATE AGAINST HERPES ZOSTER: A COST-EFFECTIVENESS ANALYSIS
Phuc Le, PhD, MPH and Michael Rothberg, MD, MPH, Medicine Institute Cleveland Clinic, Cleveland, OH
PS2-7

COST EFFECTIVENESS OF DABIGATRAN, APIXABAN, RIVAROXABAN, EDOXABAN AND WARFARIN FOR ISCHEMIC STROKE PROPHYLAXIS AMONG PATIENTS WITH ATRIAL FIBRILLATION: US PRIVATE PAYER'S PERSPECTIVE
Anuj Shah, B. Pharm1, Anand Shewale, MS2, Corey Hayes, Pharm D MPH1 and Bradley Martin, Pharm D PhD1, (1)University of Arkansas for Medical Sciences, Little Rock, AR, (2)University of Arkansas for Medical Sciences, LITTLE ROCK, AR
PS2-8

THE COST-EFFECTIVENESS OF A DECISION AID FOR PATIENTS CONSIDERING TOTAL HIP OR KNEE ARTHROPLASTY: SUB-ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL
Logan Trenaman, MSc1, Nick Bansback, PhD1, Stirling Bryan, PhD2, David O. Meltzer, MD, PhD3, Geoffrey Dervin, MD4, Gillian Hawker, MD5, Monica Taljaard, PhD6, Peter Tugwell, MD6 and Dawn Stacey, PhD6, (1)University of British Columbia; Centre for Clinical Epidemiology and Evaluation; Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, (2)University of British Columbia; Centre for Clinical Epidemiology and Evaluation, Vancouver, BC, Canada, (3)University of Chicago, Chicago, IL, (4)The Ottawa Hospital, Ottawa, ON, Canada, (5)University of Toronto, Toronto, ON, Canada, (6)University of Ottawa; Ottawa Health Research Institute, Ottawa, ON, Canada
PS2-9

COST-EFFECTIVENESS OF PROPHYLACTIC PERIOPERATIVE BETA-BLOCKERS USE IN PATIENTS UNDERGOING CARDIAC OR HIGH-RISK NON-CARDIAC SURGERY
Melissa Giraldo, MD and Kenneth Smith, MD, MS, University of Pittsburgh, Pittsburgh, PA
PS2-11

PREFERENCE AGGREGATION IN THE HEALTH UTILITIES INDEX MARK 2 AND 3
Barry Dewitt1, Janel Hanmer, MD, PhD2 and Alexander Davis1, (1)Department of Engineering & Public Policy, Carnegie Mellon University, Pittsburgh, PA, (2)The University of Pittsburgh, Pittsburgh, PA
PS2-12

MICROSIMULATION METHODS FOR POLICY ANALYSIS: THE CASE OF THE CADILLAC TAX
Coleman Drake, Fernando Alarid-Escudero, MS, Lucas Higuera, MA and Roger Feldman, PhD, University of Minnesota, Minneapolis, MN
PS2-13

VALUE OF INDIVIDUALIZED INFORMATION IN COST-EFFECTIVENESS ANALYSIS: WHEN IS AN OUTCOME PREDICTION MODEL WORTH USING?
Natalia Olchanski, MS, Joshua T. Cohen, Ph.D., Peter J. Neumann, Sc.D., John B. Wong, MD and David M. Kent, MD, MSc, Tufts Medical Center, Boston, MA
PS2-14

USING MACHING LEARNING TO POPULATE A MARKOV MODEL BY MINING BIG DATA DIRECTLY FROM A HOSPITAL EHR
William Padula, Ph.D.1, Mary Beth Makic, PhD, RN2, Ziv Epstein3, Jonathan Gemmell, PhD4, Manish Mishra, MD, MPH5 and David O. Meltzer, MD, PhD1, (1)University of Chicago, Chicago, IL, (2)University of Colorado, Aurora, CO, (3)Pomona College, Claremont, CA, (4)DePaul University, Chicago, IL, (5)Geisel School of Medicine at Dartmouth, Hanover, NH
PS2-15

A BAYESIAN APPROACH TO EPIDEMIOLOGIC ESTIMATION FOR POLICY MODELS IN THE PRESENCE OF SPARSE DATA: THE EXAMPLE OF HEPATITIS C PREVALENCE AMONG INJECTION DRUG USERS
Jake R. Morgan, MS1, Benjamin P. Linas, MD, MPH2, Mai T. Pho, MD MPH3, Joshua A. Salomon, PhD4 and Laura F. White, PhD1, (1)Boston University, Boston, MA, (2)Boston Medical Center, Boston, MA, (3)University of Chicago, Chicago, IL, (4)Harvard School of Public Health, Boston, MA
PS2-17

A NON-ITERATIVE METHOD OF IDENTIFYING THE COST-EFFECTIVENESS FRONTIER USING NET MONETARY BENEFITS AND ITS GRAPHICAL INTERPRETATION
Sze-chuan Suen, MS, Department of Management Science and Engineering, Stanford University, Stanford, CA and Jeremy D. Goldhaber-Fiebert, PhD, Stanford Health Policy, Centers for Health Policy and Primary Care and Outcomes Research, Department of Medicine, Stanford University, Stanford, CA
PS2-19

INTRODUCING THE CURVE OF OPTIMAL SAMPLE SIZE (COSS): A GRAPHIC REPRESENTATION OF OPTIMAL SAMPLE SIZE BY WILLINGNESS-TO-PAY THRESHOLD
Fernando Alarid-Escudero, MS1, Eric Jutkowitz2, Karen M. Kuntz, ScD1 and Hawre Jalal, PhD3, (1)University of Minnesota, Minneapolis, MN, (2)University of Minnesota School of Public Health, Minneapolis, MN, (3)Department of Health Policy and Management, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA
PS2-21

DOES SIZE MATTER? A METHOD FOR ADAPTIVELY DETERMINING CYCLE LENGTH IN A STATE-TRANSITION MODEL
Rowan Iskandar, MA, Fernando Alarid-Escudero, MS and Karen M. Kuntz, ScD, University of Minnesota, Minneapolis, MN
PS2-22

A NON-SAMPLING BASED METHOD FOR PROPAGATING PARAMETER UNCERTAINTY INTO STATE-TRANSITION MODELS
Rowan Iskandar, MA and Karen M. Kuntz, ScD, University of Minnesota, Minneapolis, MN
PS2-25

ESTIMATING THE PREVALENCE OF HEPATITIS C IN PENNSYLVANIA MEDICAID USING A MICROSIMULATION MODEL
Mina Kabiri, MS1, Walid Gellad, MD, MPH1, Jagpreet Chhatwal, PhD2, Michael Dunn, MD, FACP3, Julie Donohue, PhD1 and Mark S. Roberts, MD, MPH1, (1)Department of Health Policy and Management, University of Pittsburgh, Pittsburgh, PA, (2)The University of Texas MD Anderson Cancer Center, Houston, TX, (3)Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, PA
PS2-26

DEVELOPMENT OF A CLINICAL FORECASTING MODEL FOR DETECTING COMORBID DEPRESSION AMONG PATIENTS WITH DIABETES AND AN APPLICATION IN DEPRESSION SCREENING POLICYMAKING
Haomiao Jin, MS1, Shinyi Wu, PhD1 and Paul Di Capua, MD, MBA2, (1)University of Southern California, Los Angeles, CA, (2)University of California, Los Angeles, Los Angeles, CA
PS2-27

IMPACT OF EXPANDING THE NATIONAL SALT REDUCTION INITIATIVE: A MATHEMATICAL MODEL OF BENEFITS AND RISKS OF POPULATION-LEVEL SODIUM REDUCTION
Sung Eun Choi, SM1, Margaret L. Brandeau, PhD2 and Sanjay Basu, MD, PhD1, (1)Stanford University, Stanford, CA, (2)Department of Management Science and Engineering, Stanford University, Stanford, CA
PS2-28

USING DECOMPOSITION ANALYSIS TO UNDERSTAND THE IMPACT OF SODIUM ON DISPARITIES IN BLOOD PRESSURE IN THE UNITED STATES
Sung Eun Choi, SM1, Arjumand Siddiqi, ScD2 and Sanjay Basu, MD, PhD1, (1)Stanford University, Stanford, CA, (2)University of Toronto, Toronto, ON, Canada
PS2-29

BREAST DENSITY LEGISLATION AND BREAST CANCER STAGE AT DIAGNOSIS
Ilana Richman, MD, Stanford University/VA Palo Alto, Stanford, CA, Steven Asch, PhD, HSR&D Center for Health Care Evaluation, Menlo Park, CA, Douglas K. Owens, MD, MS, VA Palo Alto Health Care System, Palo Alto, CA and Jay Bhattacharya, MD, PhD, Stanford University, Stanford, CA
PS2-31

ESTIMATION OF FIBROSIS PROGRESSION RATES FOR CHRONIC HEPATITIS C: A SYSTEMATIC REVIEW AND META-ANALYSIS UPDATE
Aysegul Erman1, Tawnya Hansen2, Joanna M. Bielecki, BSC, MISt3, Murray D Krahn, MD, MSc, FRCPC3 and Hla-Hla Thein, MD, MPH, PhD4, (1)Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada, (2)Department of Medicine, University Health Network, University of Toronto, Toronto, ON, Canada, (3)Toronto Health Economics and Technology Assessment (THETA) Collaborative, University of Toronto, Toronto, ON, Canada, (4)Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
PS2-32

VALUE OF ADDITION OF HPV VACCINATION TO ANAL PRECANCEROUS LESION TREATMENT IN OLDER MSM—DO WE NEED FURTHER EVIDENCE?
Ashish A. Deshmukh, Ph.D., M.P.H.1, Scott B. Cantor, Ph.D.1, Elisabeth A.L. Fenwick, PhD2, Elizabeth Chiao, M.D., M.P.H.3, Alan Nyitray, Ph.D.4, Prajnan Das, M.D., M.S., M.P.H.1 and Jagpreet Chhatwal, PhD1, (1)The University of Texas MD Anderson Cancer Center, Houston, TX, (2)ICON plc, Oxford, United Kingdom, (3)Baylor College of Medicine, Houston, TX, (4)The University of Texas School of Public Health, Houston, TX
PS2-33

MANAGEMENT OF EPILEPSY IN WOMEN CONTEMPLATING PREGNANCY: A DECISION ANALYSIS MODEL
Rohan D'Souza1, Ari Breiner2, Beate Sander3, Kellie Murphy1, Sarah Bermingham4 and Murray D Krahn, MD, MSc, FRCPC4, (1)Mount Sinai Hospital, Toronto, ON, Canada, (2)Institute of Health Policy Management and Evaluation, Toronto, ON, Canada, (3)Public Health Ontario, Toronto, ON, Canada, (4)Toronto Health Economics and Technology Assessment (THETA) Collaborative, University of Toronto, Toronto, ON, Canada
PS2-34

BETTER EPIDEMIC CONTROL FOR FUTURE AFRICAN EBOLA OUTBREAKS: DYNAMIC SIMULATION MODELING CALIBRATION AND ANALYSIS
Kejing Jiang, Stanford University Department of Management Science and Engineering, Stanford, CA, Jason Andrews, Stanford University School of Medicine, Stanford, CA and Jeremy D. Goldhaber-Fiebert, PhD, Stanford Health Policy, Centers for Health Policy and Primary Care and Outcomes Research, Department of Medicine, Stanford University, Stanford, CA
PS2-35

ASSESSING THE IMPACT OF RECENCY EFFECT IN SURGERY
Vlad V. Simianu, MD1, Anirban Basu, PhD2, Rafael Alfonso-Cristancho, MD, MSc, PhD3, Abraham D. Flaxman, PhD4 and David R. Flum, MD, MPH1, (1)Department of Surgery, University of Washington, Seattle, WA, (2)Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Seattle, WA, (3)Surgical Outcomes Research Center (SORCE), University of Washington, Seattle, WA, (4)Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA
PS2-37

DO STAKEHOLDER PREFERENCES FOR ENGAGEMENT IN PEDIATRIC ATTENTION-DEFICIT/HYPERACTIVITY DISORDER TREATMENT CORRELATE WITH REPORTED OUTCOMES? A BEST WORST SCALING EXPERIMENT
Melissa Ross, MA1, John F.P. Bridges, PhD2, Xinyi Ng, BSc (Pharm)3, Emily J. Frosch, M.D.4, Gloria M. Reeves, M.D.5 and Susan dosReis, PhD1, (1)University of Maryland School of Pharmacy, Baltimore, MD, (2)Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, (3)University of Maryland Baltimore, Baltimore, MD, (4)Johns Hopkins School of Medicine, Baltimore, MD, (5)University of Maryland School of Medicine, Baltimore, MD
PS2-38

HEALTH UTILITIES IN ADULTS WITH CHRONIC PAIN
Mary-Ellen Hogan, BScPhm, PharmD, MSc1, Nicholas Mitsakakis, MSc PhD2, Vibhuti Shah, MD MSc3, Joel Katz, BA, MA, PhD4, Anna Taddio, BScPhm, MSc, PhD5 and Murray D Krahn, MD, MSc, FRCPC2, (1)Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada, (2)Toronto Health Economics and Technology Assessment (THETA) Collaborative, University of Toronto, Toronto, ON, Canada, (3)Institute of Health Policy, Management and Evaluation, University of Toronto, Department of Paediatrics, Mount Sinai Hospital, Toronto, ON, Canada, (4)Department of Psychology, York University, Toronto General Research Institute and Department of Anesthesia and Pain Management, University Health Network, Toronto, ON, Canada, (5)Leslie Dan Faculty of Pharmacy, University of Toronto; Department of Child Health Evaluative Sciences, Pharmacy, Hospital for Sick Children, Toronto, ON, Canada
PS2-39

DO “WARM UP” EXERCISES IMPACT UTILITY? EVALUATING ANCHORING BIAS IN PEDIATRIC UTILITY ELICITATION
Rohit Tejwani, MS, Hsin-Hsiao Wang, MD, MPH and Jonathan Routh, MD, MPH, Duke University School of Medicine, Durham, NC
PS2-40

USING BEST-WORST SCALING TO ELICIT PATIENT PREFERENCES FOR SYMPTOM CONTROL, SIDE-EFFECTS AND PROCESS CHARACTERISTICS OF TREATMENTS IN PARKINSON'S DISEASE
Marieke G.M. Weernink, MSc, Karin G.M. Groothuis-Oudshoorn, PhD, Maarten J. IJzerman, PhD and Janine A. van Til, PhD, University of Twente, Enschede, Netherlands
PS2-41

DISEASE SPECIFIC PATIENT REPORTED OUTCOME MEASURES IN ATRIAL FIBRILLATION: SYSTEMATIC REVIEW AND ASSESSMENT OF THE MEASUREMENT PROPERTIES
Devender Dhanda, MS, MBA and Emily Beth Devine, PhD, PharmD, MBA, University of Washington, Seattle, WA
PS2-43

ENGAGING PATIENTS AND OTHER STAKEHOLDERS IN THE DEVELOPMENT OF PATIENT DECISION AIDS: COMPARISONS OF CURRENT PRACTICES WITH USER-CENTERED DESIGN
Gratianne Vaisson, MSc1, Michèle Dugas, BA1, Thierry Provencher1, Érik Breton, PhD1, Selma Chipenda Dansokho, PhD1, Heather Colquhoun, PhD2, Angela Fagerlin, PhD3, Anik Giguère, PhD1, Sholom Glouberman, PhD4, Lynne Haslett, RN, NP, MEd5, Aubri S. Hoffman, PhD6, Noah Ivers, MD, PhD, CCFP7, France Legare, MD, PhD, CCFP1, Jean Legare8, Carrie A. Levin, PhD9, Karli Lopez, AA10, Victor M. Montori, MD, MSc11, Jean-Sébastien Renaud, PhD1, Kerri Sparling, BA12, Dawn Stacey, RN, PhD, CON (C)13, Marie-Ève Trottier, BA1, Robert J. Volk, PhD14, William Witteman, MISt15 and Holly O. Witteman, PhD1, (1)Université Laval, Quebec City, QC, Canada, (2)University of Toronto, Toronto, ON, Canada, (3)VA Ann Arbor Healthcare System & University of Michigan, Ann Arbor, MI, (4)Patients Canada, Toronto, ON, Canada, (5)East End Community Health Centre, Toronto, ON, Canada, (6)Geisel School of Medicine at Dartmouth College, Lebanon, NH, (7)Women's College Hospital, Toronto, ON, Canada, (8)Arthritis Society, Quebec, QC, Canada, (9)Informed Medical Decision Foundation, Healthwise, Boston, MA, (10)Stone Soup Group, Anchorage, AK, (11)Knowledge and Evaluation Research Unit - Mayo Clinic, Rochester, MN, (12)Six Until Me, East Greenwich, RI, (13)University of Ottawa, Ottawa, ON, Canada, (14)The University of Texas MD Anderson Cancer Center, Houston, TX, (15)CHU de Québec, Québec, QC, Canada
PS2-44

PATIENT PREFERENCES IN TYPE 2 DIABETES - DEVELOPING A STATED-PREFERENCE INSTRUMENT USING A COMMUNITY ENGAGEMENT APPROACH
Ellen Janssen, BA1, Jodi Segal, MD, MPH2 and John Bridges, PhD, MEc1, (1)Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, (2)Johns Hopkins School of Medicine, Baltimore, MD
PS2-45

HEALTH UTILITIES IN MARGINALIZED CHRONIC HEPATITIS C PATIENTS PARTICIPATING IN A COMMUNITY-BASED HEPATITIS C PROGRAM
Yasmin Saeed, BScPhm1, Kate Mason2, Suzanne Chung3, Jason Altenberg2, Jeff Powis, MD4, Julie Bruneau, MD5, Jordan J. Feld, MD6, Zeny Feng, PhD7, Nicholas Mitsakakis, MSc PhD3, Robert Myers, MD8, Valeria E. Rac, MD, PhD3, Karen E Bremner, BSc9, Murray D Krahn, MD, MSc, FRCPC3 and William W. L. Wong, Ph.D.3, (1)Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada, (2)South Riverdale Community Health Centre, Toronto, ON, Canada, (3)Toronto Health Economics and Technology Assessment (THETA) Collaborative, University of Toronto, Toronto, ON, Canada, (4)Toronto East General Hospital, Toronto, ON, Canada, (5)Department of Family Medicine, Université de Montréal, Montreal, QC, Canada, (6)Toronto Centre for Liver Disease, University Health Network, Toronto, ON, Canada, (7)Department of Mathematics and Statistics, University of Guelph, Guelph, ON, Canada, (8)Department of Medicine, University of Calgary, Calgary, AB, Canada, (9)University Health Network, Toronto, ON, Canada
PS2-46

COMPARING THE ACCURACY OF THE CONSTANT PROPORTIONAL RISK POSTURE VERSUS DELTA MODEL: MODELING THE STANDARD-GAMBLE - TIME TRADE-OFF RELATIONSHIP
David Chartash, BEngSc, MHSc1, Aaron Carroll, MD, MS2 and Stephen M. Downs, MD, MS1, (1)Children's Health Services Research Indiana University School of Medicine, Indianapolis, IN, (2)Pediatric and Adolescent Comparative Effectiveness Research Indiana University School of Medicine, Indianapolis, IN
PS2-49

RACIAL CONCORDANCE AND PERCEPTION OF HEALTHCARE PROVIDER'S COMMUNICATION SKILLS: DOES SOCIOECONOMIC STATUS MATTER?
Anushree Vichare, MBBS, MPH and Tiffany Green, Ph.D, Department of Healthcare Policy and Research, School of Medicine, Virginia Commonwealth University, Richmond, VA
PS2-50

EXPANDED CHOICE SETS INCREASE PATIENTS' WILLINGNESS TO COMPLETE ADVANCE DIRECTIVES
Katherine Courtright, M.D.1, Vanessa Madden, B.Sc.1, Nicole Gabler, Ph.D.1, Elizabeth Cooney, MPH1, Jennifer Kim, B.S.1, Nicole Herbst, M.D.1, Jennifer Whealdon, B.S.1, Lauren Burgoon, M.A.2, Karol Szymula1, Moses Flash, B.A.3, Laura Dember, M.D.1 and Scott Halpern, M.D., Ph.D.1, (1)University of Pennsylvania, Philadelphia, PA, (2)Jefferson University, Philadelphia, PA, (3)Massachusetts General Hospital, Boston, MA
PS2-51

INTEREST IN CANCER SCREENING TESTS THAT LACK BENEFITS
Katy Valentine, Columbia, MO and Laura D. Scherer, PhD, University of Missouri, Columbia, MO
PS2-55

DO PRIMARY CARE CLINICIANS ASK PATIENTS WHAT MATTERS TO THEM? AN OBSERVATIONAL STUDY IN 5 FAMILY MEDICINE CLINICS
Gisèle Diendéré, MD1, Selma Chipenda Dansokho, PhD1, Anne-Sophie Julien, MSc2, Philippe Jacob1, Sonia Mahmoudi1, Natalia Arias3, Laurie Pilote, MD1, Roland Grad, MD MSc4, France Legare, MD, PhD, CCFP1, Anik Giguère, PhD1, Luc Côté, PhD1 and Holly O. Witteman, PhD1, (1)Université Laval, Quebec City, QC, Canada, (2)CHU de Québec, Québec, QC, Canada, (3)Universidad de Cantabria, Cantabria, Spain, (4)McGill University, Montreal, QC, Canada
PS2-56

PREFERENCES AND PRACTICES OF PATIENTS WITH LUNG DISEASES AND THEIR HEALTHCARE PROVIDERS REGARDING ADVANCE CARE PLANNING: A SYSTEMATIC REVIEW
Lea J Jabbarian, MSc, Ida J Korfage, MSc, PhD, Agnes van der Heide, MD, PhD and Judith AC Rietjens, PhD, Department of Public Health, Erasmus University Medical Center, Rotterdam, Netherlands
PS2-57

IMPLICATIONS OF THE NATURALIST ORIENTATION FOR VACCINE ACCEPTANCE
Niraj Patel, Columbia, MO and Laura D. Scherer, PhD, University of Missouri, Columbia, MO
PS2-58

FIRST USER EXPERIENCES FROM A MULTI-CENTER IMPLEMENTATION OF A WEB-BASED PROSTATE CANCER TREATMENT DECISION AID IN THE NETHERLANDS
Maarten Cuypers, MSc.1, Romy R.E.D. Lamers, MD2, Paul J.M. Kil, MD, PhD2, Lonneke V. van de Poll-Franse, PhD1 and Marieke de Vries, PhD1, (1)Tilburg University, Tilburg, Netherlands, (2)St. Elisabeth Hospital, Tilburg, Netherlands
PS2-59

CHOOSING TREATMENTS CONGRUENT WITH VALUES: DO PATIENTS NEED HELP AND DO DECISION AIDS PROVIDE IT? SUB-ANALYSIS OF A SYSTEMATIC REVIEW
Sarah Munro, MA, University of British Columbia, Vancouver, BC, Canada, Dawn Stacey, RN, PhD, CON (C), University of Ottawa, Ottawa, ON, Canada, Krystina B. Lewis, RN, MN, CCN(C), University of Ottawa Heart Institute, Ottawa, ON, Canada and Nick Bansback, PhD, University of British Columbia; Centre for Clinical Epidemiology and Evaluation; Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada
See more of: 37th Annual Meeting of the Society for Medical Decision Making
<< Previous Session | Next Session >>